POLISCOPE
Back to feed
FEDERALcongressional record
High Impact

American Biotechnology Competitiveness Act (SA 6334)

Original title: Text of Senate Amendment 6334

June 24, 2026

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

This legislation would create new federal oversight for companies that synthesize DNA, establish a $150 million cloud-based research network, and authorize $120 million for a new biopharmaceutical manufacturing center to reduce reliance on foreign supply chains.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Synthetic nucleic acid providers

Must implement new screening protocols for orders and customers and undergo mandatory conformity assessments.

Biopharmaceutical manufacturers

May access the new Innovation Center for research, workforce training, and infrastructure support.

Institutions of higher education

Eligible to apply for designation as nodes in the cloud laboratory network and participate in biomanufacturing research.

What changed

Last recorded activity June 24, 2026.

What's next

Next step not available in the current record.

Summary

This amendment proposes a national strategy to secure U.S. biotechnology leadership by regulating , establishing a cloud-based laboratory network, and creating a national biopharmaceutical manufacturing center. It aims to mitigate biosecurity risks from synthetic pathogens while boosting domestic manufacturing and research capabilities.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Why It Matters

This legislation would create new federal oversight for companies that synthesize DNA, establish a $150 million cloud-based research network, and authorize $120 million for a new biopharmaceutical manufacturing center to reduce reliance on foreign supply chains.

Frequently Asked Questions

What is a 'covered provider' under this act?
A covered provider is any person or entity that synthesizes and sells synthetic nucleic acids or produces/distributes equipment for synthesizing nucleic acids, excluding those selling within a commercial entity for internal research.
How will the government ensure my data remains private?
The act mandates that customer information submitted for screening or sandbox participation be kept confidential and exempt from public disclosure under the Freedom of Information Act.
What is a 'programmable cloud laboratory'?
A physical laboratory equipped with robotics and AI that can be securely and remotely programmed to conduct experiments and collect data.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Sponsors

Show 2 more sponsors

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Shift toward automated biosecurity

The bill explicitly moves away from voluntary guidelines toward mandatory, federally-enforced screening protocols for DNA synthesis, signaling a major shift in biosecurity policy.

Connected Entities

personMr. PadillaCo-sponsor of the amendment.Map →
personMr. FettermanCo-sponsor of the amendment.Map →
personMs. KlobucharCo-sponsor of the amendment.Map →
personMr. YoungLead sponsor of the amendment.Map →
organizationDepartment of CommercePrimary agency for biosecurity regulation and innovation programs.Map →
organizationNational Science FoundationOversees the National Programmable Cloud Laboratories Network.Map →
personMr. BuddCo-sponsor of the amendment.Map →
personMr. CoonsCo-sponsor of the amendment.Map →
organizationNational Institute of Standards and TechnologyResponsible for technical standards and the biopharmaceutical center.Map →
personMr. CottonCo-sponsor of the amendment.Map →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100
  • Significance85
    How much this matters to a regular citizen
  • Controversy40
    Intensity of disagreement among stakeholders
  • Entertainment10
    Compellingness for a non-policy-wonk reader
  • Buzz30
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record